Antimicrobial Resistance Research Center, Mashhad University of Medical Science, Mashhad, Iran.
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Bioengineered. 2019 Dec;10(1):689-696. doi: 10.1080/21655979.2019.1694388.
Epstein-Barr virus (EBV) associated with several diseases such as contagious mononucleosis chronic active EBV infection, and diverse sorts of malignant tumors. Therefore, using applicable vaccines could be advantageous for public health. Yet, the vaccine has been unavailable to protect from EBV so far. In the current study, to develop a multi-peptide vaccine for EBV and assess its expression in yeast system, three immunodominant sequences in glycoprotein (gp) 85, gp350 and latent membrane protein 1 (LMP1) were chosen. To construct fusion peptide, -GGGGS- liker was applied. After cloning the fusion peptide in the pPICZαA expression vector, this recombinant vector processed and transfected into host cells. The expression of high level of EBV fusion peptide was confirmed by dot blot and SDS-PAGE procedures. The is capable of supporting EBV fusion peptide expression. The application of this fusion peptide as a peptide vaccine to fight EBV is suggested.
EB 病毒(EBV)与多种疾病相关,如传染性单核细胞增多症、慢性活动性 EBV 感染和多种恶性肿瘤。因此,使用适用的疫苗可能对公共卫生有益。然而,到目前为止,还没有疫苗可以预防 EBV。在本研究中,为了开发一种用于 EBV 的多肽疫苗并评估其在酵母系统中的表达,选择了糖蛋白(gp)85、gp350 和潜伏膜蛋白 1(LMP1)中的三个免疫优势序列。为了构建融合肽,应用了 -GGGGS- 类似物。将融合肽克隆到 pPICZαA 表达载体后,该重组载体经过处理并转染到宿主细胞中。通过点印迹和 SDS-PAGE 程序证实了 EBV 融合肽的高水平表达。毕赤酵母是能够支持 EBV 融合肽表达的。建议将该融合肽作为一种肽疫苗用于对抗 EBV。